363 related articles for article (PubMed ID: 30870721)
1. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
Guo F; Yang Z; Kulbe H; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 Oct; 118():109371. PubMed ID: 31545281
[TBL] [Abstract][Full Text] [Related]
3. Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death.
Guo F; Yang Z; Sehouli J; Kaufmann AM
Curr Oncol; 2022 Apr; 29(4):2808-2822. PubMed ID: 35448203
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
[TBL] [Abstract][Full Text] [Related]
5. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
Choi SA; Choi JW; Wang KC; Phi JH; Lee JY; Park KD; Eum D; Park SH; Kim IH; Kim SK
Neuro Oncol; 2015 Jun; 17(6):810-21. PubMed ID: 25378634
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effect of disulfiram/copper on human cervical cancer cell lines and LGR5-positive cancer stem-like cells.
Cao HZ; Yang WT; Zheng PS
BMC Cancer; 2022 May; 22(1):521. PubMed ID: 35534815
[TBL] [Abstract][Full Text] [Related]
7. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
8. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway.
Islam SS; Al-Sharif I; Sultan A; Al-Mazrou A; Remmal A; Aboussekhra A
Mol Carcinog; 2018 Mar; 57(3):333-346. PubMed ID: 29073729
[TBL] [Abstract][Full Text] [Related]
9. Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts.
Yao W; Qian X; Ochsenreither S; Soldano F; DeLeo AB; Sudhoff H; Oppel F; Kuppig A; Klinghammer K; Kaufmann AM; Albers AE
Cells; 2021 Feb; 10(3):. PubMed ID: 33671083
[TBL] [Abstract][Full Text] [Related]
10. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
Liu P; Brown S; Goktug T; Channathodiyil P; Kannappan V; Hugnot JP; Guichet PO; Bian X; Armesilla AL; Darling JL; Wang W
Br J Cancer; 2012 Oct; 107(9):1488-97. PubMed ID: 23033007
[TBL] [Abstract][Full Text] [Related]
12. Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram.
Sun T; Yang W; Toprani SM; Guo W; He L; DeLeo AB; Ferrone S; Zhang G; Wang E; Lin Z; Hu P; Wang X
Cell Commun Signal; 2020 Mar; 18(1):36. PubMed ID: 32138738
[TBL] [Abstract][Full Text] [Related]
13. The interaction of disulfiram and H
Read E; Milford J; Zhu J; Wu L; Bilodeau M; Yang G
Toxicol Appl Pharmacol; 2021 Sep; 426():115642. PubMed ID: 34242567
[TBL] [Abstract][Full Text] [Related]
14. Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase.
Skrott Z; Majera D; Gursky J; Buchtova T; Hajduch M; Mistrik M; Bartek J
Oncogene; 2019 Oct; 38(40):6711-6722. PubMed ID: 31391554
[TBL] [Abstract][Full Text] [Related]
15. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram/Copper Suppresses Cancer Stem Cell Activity in Differentiated Thyroid Cancer Cells by Inhibiting BMI1 Expression.
Ni YL; Chien PJ; Hsieh HC; Shen HT; Lee HT; Chen SM; Chang WW
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362068
[TBL] [Abstract][Full Text] [Related]
17. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance.
Song W; Tang Z; Shen N; Yu H; Jia Y; Zhang D; Jiang J; He C; Tian H; Chen X
J Control Release; 2016 Jun; 231():94-102. PubMed ID: 26928530
[TBL] [Abstract][Full Text] [Related]
18. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
Liu P; Kumar IS; Brown S; Kannappan V; Tawari PE; Tang JZ; Jiang W; Armesilla AL; Darling JL; Wang W
Br J Cancer; 2013 Oct; 109(7):1876-85. PubMed ID: 24008666
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties.
Yip NC; Fombon IS; Liu P; Brown S; Kannappan V; Armesilla AL; Xu B; Cassidy J; Darling JL; Wang W
Br J Cancer; 2011 May; 104(10):1564-74. PubMed ID: 21487404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]